Merck Expands Protein A Capabilities with JSR Chromatography Acquisition
The company says the acquisition will strengthen downstream antibody manufacturing and help biopharma customers scale more efficiently.
False
The company says the acquisition will strengthen downstream antibody manufacturing and help biopharma customers scale more efficiently.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
May 27, 2025
6 min read
Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.
December 1, 2014
0 min read
Upstream processes in biopharma manufacturing are growing ever more efficient; conversely, downstream processing is increasingly a bottleneck. Can a new generation of chromatography techniques and technologies get things moving again?
April 2, 2025
5 min read
Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.
April 7, 2025
6 min read
Meet one company and its new drug candidate in the fight against gram-negative bacterial infections.
False
Affiliations:
Specialties:
Areas of Expertise: